ライフサイエンスコーパス: lasofoxifene

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 events and stroke, whereas women assigned to lasofoxifene 0.25 mg/d had a lower risk of stroke.

2 The reduction in CHD events with lasofoxifene 0.25 mg/d was not significant (hazard ratio

3 o 80 years of age with osteoporosis received lasofoxifene 0.25 mg/d, lasofoxifene 0.5 mg/d, or placeb

4 In postmenopausal women with osteoporosis, lasofoxifene 0.5 mg/d for 5 years reduced the risk of CH

5 asofoxifene (PEARL) trial, women assigned to lasofoxifene 0.5 mg/d had a lower risk of major coronary

6 The effectiveness of lasofoxifene 0.5 mg/d in reducing CHD events was similar

7 D events, and evaluate whether the effect of lasofoxifene 0.5 mg/d is consistent across different cat

8 Compared with placebo, lasofoxifene 0.5 mg/d reduced the risk of major CHD even

9 ificant reduction in risk of CHD events with lasofoxifene 0.5 mg/d was due primarily to lower risks o

10 steoporosis received lasofoxifene 0.25 mg/d, lasofoxifene 0.5 mg/d, or placebo for 5 years.

11 Lasofoxifene and arzoxifene are two newer SERMs that hav

12 Two newer drugs in this class, lasofoxifene and arzoxifene, also show efficacy and poss

13 d ratios were <1.0, no significant effect of lasofoxifene at 0.5 mg/d was demonstrated for coronary d

14 Lasofoxifene at a dose of 0.25 mg per day, as compared w

15 In postmenopausal women with osteoporosis, lasofoxifene at a dose of 0.5 mg per day was associated

16 Lasofoxifene at a dose of 0.5 mg per day, as compared wi

17 femoral neck or spine to receive once-daily lasofoxifene (at a dose of either 0.25 mg or 0.5 mg) or

18 entified: tamoxifen, raloxifene, arzoxifene, lasofoxifene, exemestane, and anastrozole.

19 in the placebo group, 7.0 in the lower-dose lasofoxifene group, and 5.7 in the higher-dose lasofoxif

20 e placebo group, two women in the lower-dose lasofoxifene group, and two women in the higher-dose las

21 fene group, and two women in the higher-dose lasofoxifene group.

22 sofoxifene group, and 5.7 in the higher-dose lasofoxifene group.

23 Both doses of lasofoxifene increased the risk of venous thromboembolic

24 novel selective estrogen receptor modulator lasofoxifene (LAS) to inhibit the development of mammary

25 The effects of lasofoxifene on the risk of fractures, breast cancer, an

26 enopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial, women assigned to lasofoxife

27 ERMs; tamoxifen, raloxifene, arzoxifene, and lasofoxifene) with placebo, or in one study with tamoxif

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。